Linked Data API

Show Search Form

Search Results

753958
star this property registered interest false more like this
star this property date less than 2017-07-19more like thismore than 2017-07-19
star this property answering body
Department of Health more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Radioisotopes: Imports more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL1104 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-07-31more like thismore than 2017-07-31
unstar this property answer text <p>The Government is fully aware of the importance of molybdenum-99 and the reliance on this medical radioisotope for diagnostic procedures in the National Health Service. The United Kingdom’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in everyone’s interest to not disrupt the timely access of treatment to patients and to ensure that cross-border trade with the European Union and Euratom is as frictionless as possible.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2017-07-31T13:38:56.527Zmore like thisremove minimum value filter
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
753959
star this property registered interest false more like this
star this property date less than 2017-07-19more like thismore than 2017-07-19
star this property answering body
Department for Exiting the European Union more like this
unstar this property answering dept id 203 more like this
star this property answering dept short name Exiting the European Union more like this
star this property answering dept sort name Exiting the European Union more like this
star this property hansard heading Radioisotopes: Imports more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what terms they are seeking to agree with the European Union to ensure that no additional delays or restrictions are placed on imports of molybdenum-99 to the UK following the UK's departure from Euratom. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL1105 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-08-02more like thismore than 2017-08-02
unstar this property answer text <p>The UK’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom.</p><p>The import or export of medical radioisotopes, including molybdenum-99 is not subject to any Euratom licensing requirements.These isotopes are governed and regulated under the Euratom framework; however, Euratom places no restrictions on the export of medical isotopes to countries outside the EU.</p><p>It is in everyone’s interest to not disrupt the timely access of treatment to patients; and to ensure that cross-border trade with the EU and Euratom is as frictionless as possible.</p><p> </p> more like this
star this property answering member printed Baroness Anelay of St Johns more like this
star this property question first answered
less than 2017-08-02T14:39:06.3Zmore like thismore than 2017-08-02T14:39:06.3Z
star this property answering member
3474
star this property label Biography information for Baroness Anelay of St Johns more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
993365
star this property registered interest false more like this
star this property date less than 2018-10-22more like thismore than 2018-10-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haematological Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government (1) how many drugs were available on the NHS for the treatment of blood cancer, and (2) how much the NHS spent on blood cancer drugs, in each of the past five years. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL10893 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-05more like thismore than 2018-11-05
unstar this property answer text <p>NHS England has advised that it is not possible to provide a comprehensive list of drugs that are available specifically for blood cancer or how much the National Health Service spends on blood cancer drugs as cancer drugs are often licenced for multiple different types of cancer.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-05T14:29:39.827Zmore like thismore than 2018-11-05T14:29:39.827Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922991
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Leukaemia: Ibrutinib more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government (1) what evidence NHS England considered, (2) which clinicians it consulted, and (3) which patient groups it consulted when deciding that ibrutinib should not be prescribed to people with chronic lymphocytic leukaemia who have been in remission for more than three years. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8564 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8562 more like this
HL8563 more like this
star this property question first answered
less than 2018-06-26T12:13:53.757Zmore like thismore than 2018-06-26T12:13:53.757Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
885902
star this property registered interest false more like this
star this property date less than 2018-04-17more like thismore than 2018-04-17
star this property answering body
Department for Business, Energy and Industrial Strategy more like this
unstar this property answering dept id 201 more like this
star this property answering dept short name Business, Energy and Industrial Strategy more like this
star this property answering dept sort name Business, Energy and Industrial Strategy more like this
star this property hansard heading Artificial Intelligence more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government by what metrics they will determine whether the UK has become “the go-to destination for AI innovation and investment”, as set out in their Industrial Strategy White Paper; and by what date they intend to achieve that aim. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL6996 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-04-30more like thismore than 2018-04-30
unstar this property answer text <p>AI is emerging in its own right as a nascent industry with the potential to raise the productivity of diverse sectors and create entirely new jobs. To maximise this potential, the recently announced AI Sector Deal will establish a new AI Council to bring together respected leaders in the field from across academia and industry; a new delivery body within the government – the Office for Artificial Intelligence – to support it; and a new Centre for Data Ethics and Innovation.</p><p> </p><p>Oversight of the implementation of the Sector Deal will be led by the Office for Artificial Intelligence, which will review progress against objectives regularly.</p><p> </p><p>The new government Office for Artificial Intelligence will be established with responsibility for implementing this Sector Deal. It will support the AI Council which will oversee and drive the implementation of the deal.</p><p> </p><p>An early role for the Office for AI will be to agree implementation plans for each section of the deal, including agreed success metrics.</p><p> </p><p>Membership of the AI Council will be announced ahead of the first meeting. The main aim of the AI Council will be to provide strategic leadership and momentum in delivery.</p><p> </p><p>The Office for AI will report to the AI Council regularly and will be subject to challenge sessions from government ministers on progress in implementing the Sector Deal. The Industrial Strategy team will provide the challenge on delivery timetable, metrics and ambition on outcomes as well as providing updates and escalation to ministers across the suite of Sector Deals.</p>
star this property answering member printed Lord Henley more like this
star this property question first answered
less than 2018-04-30T16:38:54.38Zmore like thismore than 2018-04-30T16:38:54.38Z
star this property answering member
2616
star this property label Biography information for Lord Henley more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
1005628
star this property registered interest false more like this
star this property date less than 2018-11-12more like thismore than 2018-11-12
star this property answering body
Department for Business, Energy and Industrial Strategy more like this
unstar this property answering dept id 201 more like this
star this property answering dept short name Business, Energy and Industrial Strategy more like this
star this property answering dept sort name Business, Energy and Industrial Strategy more like this
star this property hansard heading Companies: Codes of Practice more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government by what process and criteria they will evaluate companies’ explanations for non-compliance with the revised UK Corporate Governance Code of July 2018; and what steps they plan to take when they deem explanations for non-compliances not to be satisfactory. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL11399 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-19more like thismore than 2018-11-19
unstar this property answer text <p>The UK Corporate Governance Code is the responsibility of the Financial Reporting Council. It is the responsibility of investors to assess the quality of reporting and engage with companies accordingly.</p><p> </p><p>The 2018 Code is a substantial revision and comes into force for accounting periods beginning on or after 1 January 2019. Reporting against the revised Code will therefore not be required until 2020 when companies publish their annual reports and accounts for the preceding year. However, the FRC intends to evaluate the extent of early adoption of the new Code in terms of reporting on the application of its Principles and compliance or otherwise with its Provisions and to publish its findings at the end of 2019.</p><p> </p><p>The FRC is the subject of an independent review being led by Sir John Kingman which is expected to report before the end of the year.</p><p> </p> more like this
star this property answering member printed Lord Henley more like this
star this property question first answered
less than 2018-11-19T15:43:10.97Zmore like thismore than 2018-11-19T15:43:10.97Z
star this property answering member
2616
star this property label Biography information for Lord Henley more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
788337
star this property registered interest false more like this
star this property date less than 2017-11-13more like thismore than 2017-11-13
star this property answering body
Department for Business, Energy and Industrial Strategy more like this
unstar this property answering dept id 201 more like this
star this property answering dept short name Business, Energy and Industrial Strategy more like this
star this property answering dept sort name Business, Energy and Industrial Strategy more like this
star this property hansard heading Small Businesses: Complaints more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government further to the Written Answer by Lord Henley on 10 November (HL2702), how many complaints from small businesses have been received by (1) the Department for Business, Energy and Industrial Strategy, and (2) the Small Business Commissioner's office, since 1 October; and of those, how many have not been accepted because of the delay in the launch of the Small Business Commissioner's complaints handling service. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL3129 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-11-20more like thismore than 2017-11-20
unstar this property answer text <p>Since 1 October, the Department for Business Energy &amp; Industrial Strategy has not received any complaints from small businesses that would be in scope of the proposed Small Business Commissioner’s complaints handling service. The office of the Small Business Commissioner has received two enquiries on behalf of small businesses, neither of which would be in scope of the proposed complaints handling service. Secondary legislation relating to this complaints handling service is currently before this House, and would need to come into force before the complaints service could launch. Subject to the will of Parliament, when it is in force small businesses will be able to submit complaints for consideration, including complaints relating to the period from 6 April 2017.</p> more like this
star this property answering member printed Lord Henley more like this
star this property question first answered
less than 2017-11-20T15:17:54.907Zmore like thismore than 2017-11-20T15:17:54.907Z
star this property answering member
2616
star this property label Biography information for Lord Henley more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922989
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how NHS England formulates approval criteria for drugs already approved by the National Institute for Health and Clinical Excellence; and how it involves (1) patients, and (2) clinicians in this process. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8562 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8563 more like this
HL8564 more like this
star this property question first answered
less than 2018-06-26T12:13:53.617Zmore like thismore than 2018-06-26T12:13:53.617Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
767939
star this property registered interest false more like this
star this property date less than 2017-10-10more like thismore than 2017-10-10
star this property answering body
Department for Exiting the European Union more like this
unstar this property answering dept id 203 more like this
star this property answering dept short name Exiting the European Union more like this
star this property answering dept sort name Exiting the European Union more like this
star this property hansard heading Regulation more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many EU-level regulatory bodies they anticipate will require the establishment of a new UK-level body as a result of the UK's departure from the EU and the conversion of EU law into UK law; and by what date they plan to have those bodies established. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL1858 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-10-23more like thismore than 2017-10-23
unstar this property answer text <p>No decisions have yet been taken on our future relationship with the EU's regulatory bodies after exiting the EU. We are carefully considering a range of options and preparing for a number of negotiation outcomes.</p><p>Prior to any decisions on establishing new UK-level bodies, the Government will, however, always look to minimise disruption and costs, which will include considering alternative options. The European Union (Withdrawal) Bill makes clear that any decision on creating new agencies would require the approval of both Houses of Parliament under the affirmative procedure.</p><p>We will continue to plan for a range of scenarios and be ready to take any necessary steps to ensure that we are ready for exit day.</p><p> </p> more like this
star this property answering member printed Baroness Anelay of St Johns more like this
star this property question first answered
less than 2017-10-23T11:50:07.407Zmore like thismore than 2017-10-23T11:50:07.407Z
star this property answering member
3474
star this property label Biography information for Baroness Anelay of St Johns more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922990
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haematological Cancer more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many Individual Funding Requests have been submitted to the NHS for the treatment of blood cancer; and of those, how many requests were (1) successful, and (2) unsuccessful. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8563 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8562 more like this
HL8564 more like this
star this property question first answered
less than 2018-06-26T12:13:53.693Zmore like thismore than 2018-06-26T12:13:53.693Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this